In a recent analysis of the clinical methylation, combined with expression data from the Cancer Genome Atlas Program (TCGA) cohort on adult AML, changes in the methylome have been linked with clinical prognosis, thus presenting the hypothesis that the effectiveness of PARP inhibition as an AML therapeutic agent to be linked to a specific AML methylome.47, 48. The gene discussed is PARP1; the disease is acute myeloid leukemia.